Protière C, Viens P, Genre D, Cowen D, Camerlo J, Gravis G, Alzieu C, Bertucci F, Resbeut M, Maraninchi D, Moatti J P
Institut Paoli-Calmettes, Regional Centre for Cancer Care, Marseilles, France.
Ann Oncol. 2000 Jan;11(1):39-45. doi: 10.1023/a:1008390027720.
Shared decision-making is increasingly advocated as an ideal model. However, very few studies have tested the feasibility of giving patients the opportunity to participate in the choice of treatment.
Women, with non-metastatic breast cancer, eligible for non-intensified adjuvant chemotherapy attending our hospital were proposed two administrations of chemotherapy and radiotherapy: a sequential and a concomitant one. Two patient-questionnaires were used to elicit motivations for their choice and their degree of comfort with the process of decision-making and one questionnaire to test physicians' ability to predict patients' choice.
Participation rate in the study was 75.3% (n = 64). Majority (64%) of patients chose the concomitant treatment. Multivariate analysis revealed that patients with a lower level of education, who discussed the choice with social circle, and who most feared side-effects were more likely to choose the sequential treatment. Physicians were able to predict patients' choice in 66% of cases. 89% of patients declared that they were fully satisfied with having participated in the choice of treatment and 79% supported shared decision-making.
Results are in favour of promoting active participation of cancer-patients in medical decision-making. The adequate degree of such participation remains however to be elicited and tested for therapeutic choices implying more difficult trade-offs between quantity and quality of life.
共同决策越来越被倡导为一种理想模式。然而,很少有研究测试给予患者参与治疗选择机会的可行性。
我院符合非强化辅助化疗条件的非转移性乳腺癌女性患者被提供两种化疗和放疗方案:序贯方案和同步方案。使用两份患者问卷来了解她们做出选择的动机以及她们对决策过程的舒适度,并使用一份问卷来测试医生预测患者选择的能力。
研究参与率为75.3%(n = 64)。大多数(64%)患者选择了同步治疗。多变量分析显示,教育程度较低、与社交圈讨论过选择且最担心副作用的患者更有可能选择序贯治疗。医生在66%的病例中能够预测患者的选择。89%的患者表示对参与治疗选择感到完全满意,79%的患者支持共同决策。
结果支持促进癌症患者积极参与医疗决策。然而,对于涉及生活质量数量与质量之间更艰难权衡的治疗选择,这种参与的适当程度仍有待确定和测试。